EMA’s Ben Venue Recommendations Confirm Interim Advice
The European Medicines Agency confirmed its initial advice and gave final recommendations for 12 out of 14 centrally authorized medicines manufactured at Ben Venue Laboratories’ Ohio site.
The medicines can continue to be prescribed as before, the EMA said today in an e-mailed statement. The drugs include Angiox, Busilvex, Vidaza, Vistide, Velcade, Ecalta diluent, Soliris, Cayston, Luminity, Mepact, Torisel and Vibativ, the EMA said.
To contact the editor responsible for this story: Kristen Hallam at firstname.lastname@example.org